Skip to main content

Table 2 Univariable analysis of factors associated with overall survival

From: Poor survival in stage IIB/C (T4N0) compared to stage IIIA (T1-2 N1, T1N2a) colon cancer persists even after adjusting for adequate lymph nodes retrieved and receipt of adjuvant chemotherapy

  Before matching After matching
Variable HR 95 % CI P-value HR 95 % CI P-value
Stage
 Stage IIB/C 2.15 (2.07, 2.24) <.0001 1.70 (1.62, 1.78) <.0001
 Stage IIIA 1.00 1.00
Age
 18–49 1.00 1.00
 50–64 1.30 (1.17, 1.45) <.0001 1.41 (1.22, 1.63) <.0001
 65–74 2.23 (2.02, 2.48) <.0001 2.48 (2.16, 2.86) <.0001
 75 and more 4.86 (4.41, 5.37) <.0001 5.12 (4.47, 5.87) <.0001
Race/ Ethnicity
 White 1.00 1.00
 Black 0.96 (0.91, 1.02) 0.19 1.06 (0.98, 1.14) 0.14
 American Indian, Aleutian, or Eskimo 0.90 (0.61, 1.33) 0.60 0.93 (0.58, 1.47) 0.75
 Asian or Pacific Islander 0.55 (0.47, 0.64) <.0001 0.62 (0.50, 0.75) <.0001
 Other 0.63 (0.46, 0.87) 0.005 0.64 (0.41, 0.99) 0.05
Facility Type
 Community cancer program 1.39 (1.31, 1.48) <.0001 1.40 (1.30, 1.52) <.0001
 Comprehensive community cancer center 1.21 (1.16, 1.26) <.0001 1.24 (1.17, 1.31) <.0001
 Academic research program 1.00 1.00
Facility Location
 New England 1.08 (0.99, 1.18) 0.10 0.94 (0.84, 1.06) 0.32
 Mid Atlantic 1.07 (0.99, 1.16) 0.07 0.98 (0.89, 1.08) 0.68
 South Atlantic 1.06 (0.99, 1.13) 0.12 1.00 (0.92, 1.09) 0.98
 East North Central 1.10 (1.03, 1.18) 0.008 1.04 (0.95, 1.14) 0.39
 East South Central 1.09 (0.998, 1.20) 0.05 1.08 (0.97, 1.21) 0.16
 West North Central 1.10 (1.005, 1.19) 0.04 1.04 (0.94, 1.16) 0.43
 West South Central 1.01 (0.92, 1.11) 0.80 0.99 (0.89, 1.11) 0.84
 Mountain 0.93 (0.83, 1.04) 0.20 0.87 (0.75, 1.01) 0.06
 Pacific 1.00 1.00
Urban/Rural Location
 Metro ≥1 million 1.00 1.00
 Metro 250 k to 1 million 1.07 (1.02, 1.12) 0.008 1.09 (1.03, 1.15) 0.004
 Urban <250 k 1.07 (1.004, 1.14) 0.04 1.06 (0.98, 1.14) 0.17
 Urban ≥ 20 k adjacent metro 1.10 (1.002, 1.21) 0.046 1.10 (0.98, 1.24) 0.09
 Urban ≥ 20 k not adjacent metro 1.04 (0.89, 1.22) 0.65 1.05 (0.87, 1.26) 0.63
 Urban <20 k adjacent metro 1.13 (1.04, 1.23) 0.006 1.06 (0.95, 1.18) 0.30
 Urban <20 k not adjacent metro 1.23 (1.10, 1.38) 0.0005 1.32 (1.15, 1.52) 0.0001
 Rural <2500 adjacent metro 1.02 (0.85, 1.24) 0.81 0.88 (0.68, 1.14) 0.33
 Rural <2500 not adjacent metro 1.12 (0.94, 1.33) 0.21 1.06 (0.85, 1.32) 0.58
Comorbidities
 0 1.00 1.00
 1 1.46 (1.40, 1.53) <.0001 1.49 (1.42, 1.58) <.0001
 2 2.29 (2.16, 2.42) <.0001 2.29 (2.13, 2.46) <.0001
Primary Site
 Cecum 1.00 1.00
 Ascending Colon 0.96 (0.91, 1.02) 0.15 1.04 (0.97, 1.11) 0.30
 Hepatic Flexure 0.97 (0.88, 1.07) 0.51 0.95 (0.84, 1.07) 0.39
 Transverse Colon 1.07 (0.997, 1.14) 0.06 0.93 (0.85, 1.02) 0.11
 Splenic Flexure 1.07 (0.96, 1.18) 0.23 0.90 (0.77, 1.04) 0.15
 Descending Colon 0.85 (0.78, 0.93) 0.0003 0.85 (0.77, 0.95) 0.003
 Sigmoid Colon 0.76 (0.72, 0.80) <.0001 0.82 (0.77, 0.87) <.0001
 Overlapping Lesions 1.19 (1.03, 1.38) 0.02 0.80 (0.62, 1.03) 0.08
 Not Otherwise Specified 1.14 (1.004, 1.29) 0.04 1.13 (0.95, 1.33) 0.17
Grade
 Well differentiated 1.00 1.00
 Moderately differentiated 1.09 (1.02, 1.16) 0.01 1.04 (0.96, 1.13) 0.37
 Poorly differentiated 1.39 (1.29, 1.50) <.0001 1.11 (1.01, 1.22) 0.03
 Undifferentiated, anaplastic 1.74 (1.53, 1.97) <.0001 1.23 (1.02, 1.48) 0.03
Surgical Margins
 No residual tumor 1.00 1.00
 With Residual tumor 1.91 (1.81, 2.02) <.0001 1.24 (1.03, 1.49) 0.02
Readmission within 30 days of Surgery
 Not readmitted 1.00 1.00
 Readmitted 1.15 (1.08, 1.22) <.0001 1.13 (1.05, 1.22) 0.002
Regional Lymph Nodes Examined
 0–11 1.34 (1.29, 1.39) <.0001 1.29 (1.23, 1.35) <.0001
 12–90 1.00 1.00
Chemotherapy
 Yes 1.00 1.00
 No 3.55 (3.41, 3.70) <.0001 3.49 (3.32, 3.67) <.0001